CMTM6 and colorectal cancer: In addition, the co-expression of CMTM6 and PD-L1 is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer, especially in patients receiving adjuvant chemotherapy (Peng et al., 2021).